FEATURE ARTICLES
What does 2026 ultimately hold for the industry? To explore that question, Lawrence Blatt, CEO of Aligos Therapeutics, sat down with me to share his perspective on the trends shaping the year ahead.
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- The Rise Of The Autonomous Pharma Plant
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- At Base Camp: Lilly's Manufacturing Capacity Journey
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-2103894533-office-business-professional-suit-woman-table]( "Navigating The Future Of Lab Developed Tests")
Navigating The Future Of Lab Developed TestsExplore the pivotal role of lab-developed tests (LDTs) in medical diagnostics, their growing regulatory scrutiny, and their future trajectory in modern healthcare to advance patient care.
-
Choosing The Right Platform: A Comparison For Regulated Industries2/22/2026
Regulated industries depend on tightly controlled review workflows, yet common tools rarely meet those demands. Explore how purpose‑built solutions strengthen compliance and help streamline timelines.
-
Navigating Digital Transformation For Pharmaceutical CDMOs10/31/2025
Discover how CDMOs can modernize operations, safeguard data integrity, and improve audit readiness with practical strategies for connecting systems and reducing validation burdens.
-
Advancing ADCs With Expertise In Payloads And Linkers2/18/2026
Discover how integrated containment, high-potency expertise, advanced chromatography, and proven linker–payload process optimization can accelerate your ADC program from early development to reliable commercial supply.
-
Learn, Confirm, Then Scale: A Leader's Guide To Transforming QC1/21/2026
Legacy lab systems hinder innovation and scalability. Explore a proven approach to modernize QC through cloud-based LIMS, starting with small pilots that validate strategy and reduce risk.
-
Molecular Properties Of PROTACs And The Relationship To Formulation Design3/4/2025
Here, we conduct a comprehensive analysis of diverse PROTAC (Proteolysis Targeting Chimeras) structures, evaluating their calculated physicochemical properties to identify key trends.
PHARMA ONLINE APP NOTES & CASE STUDIES
- A Study To Assess Organoid Size And Cell Count From 3D Image Analysis
- Performance Of Mobius® Bag Assemblies With Ultimus® Film In Truck Shipping Simulation Test
- Improve mAb Purification Process Efficiency With Mixed-Mode Resins
- How To Successfully Isolate Your T Cells
- Migrating Peptide Mapping Methods With Innovative Technology
NEWSLETTER ARCHIVE
- 02.26.26 -- At Base Camp: Lilly's Manufacturing Capacity Journey
- 02.26.26 -- STREAM Edition: Considerations For Single Use Disposables
- 02.25.26 -- Ready to design a scalable, cost optimized viral vector workflow?
- 02.25.26 -- Advanced Mixing Strategies & Process Optimization
- 02.24.26 -- Innovations Shaping The Future Of Pharma Manufacturing
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas2/26/2026
Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas.
-
Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract2/24/2026
This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest OSD site in Maple Grove, Minnesota.
-
AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois2/24/2026
AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.
-
Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania2/22/2026
ohnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.
